<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229433</url>
  </required_header>
  <id_info>
    <org_study_id>SHR2285-102</org_study_id>
    <nct_id>NCT04229433</nct_id>
  </id_info>
  <brief_title>The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Single -Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR2285 Tablets in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, single-blind, placebo-controlled, multiple-dose escalation Phase I&#xD;
      trials. 2 dose groups were designed, 12 subjects in each dose group.The drug was administered&#xD;
      single dose and multiple doses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2020</start_date>
  <completion_date type="Actual">November 8, 2020</completion_date>
  <primary_completion_date type="Actual">November 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multiple dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events and serious adverse events.</measure>
    <time_frame>Pre-dose to 7 days after multiple dose administration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter will be evaluated.</measure>
    <time_frame>Pre-dose to 3 days after single dose administration</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) for single dose of SHR2285.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) for single dose of SHR2285.</measure>
    <time_frame>Pre-dose to 3 days after single dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum concentration (Tmax) for single dose of SHR2285.</measure>
    <time_frame>Pre-dose to 3 days after single dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total clearance of the drug from plasma after oral administration (CL/F) for single dose of SHR2285.</measure>
    <time_frame>Pre-dose to 3 days after single dose administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution after non-intravenous administration (V/F) for single dose of SHR2285</measure>
    <time_frame>Pre-dose to 3 days after single dose administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to elimination half-life (T1/2) for single dose of SHR2285.</measure>
    <time_frame>Pre-dose to 3 days after single dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) for multiple dose of SHR2285.</measure>
    <time_frame>Pre-dose to 2 days after multiple dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state peak concentration (Cmax，ss) for multiple dose of SHR2285.</measure>
    <time_frame>Pre-dose to 2 days after multiple dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state valley concentration (Ctrough，ss) for multiple dose of SHR2285.</measure>
    <time_frame>Pre-dose to 2 days after multiple dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum concentration (Tmax) for multiple dose of SHR2285.</measure>
    <time_frame>Pre-dose to 2 days after multiple dose administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to elimination half-life (T1/2) for multiple dose of SHR2285.</measure>
    <time_frame>Pre-dose to 2 days after multiple dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state apparent total clearance of the drug from plasma after oral administration (CLSS/F) for multiple dose of SHR2285.</measure>
    <time_frame>Pre-dose to 2 days after multiple dose administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state apparent volume of distribution after non-intravenous administration (VSS/F) for multiple dose of SHR2285.</measure>
    <time_frame>Pre-dose to 2 days after multiple dose administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Racc) for multiple dose of SHR2285.</measure>
    <time_frame>Pre-dose to 2 days after multiple dose administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of fluctuation (PTF%) for multiple dose of SHR2285.</measure>
    <time_frame>Pre-dose to 2 days after multiple dose administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD parameter will be evaluated.</measure>
    <time_frame>Pre-dose to 3 days after single dose administration.</time_frame>
    <description>FXI activity; Change of APTT, PT, INR from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD parameter will be evaluated.</measure>
    <time_frame>Pre-dose to 2 days after multiple dose administration.</time_frame>
    <description>FXI activity; Change of APTT, PT, INR from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Thrombus</condition>
  <arm_group>
    <arm_group_label>SHR2285</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received one of 3 dose levels of SHR2285 administered as multiple oral doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received one of 3 dose levels of placebo administered as multiple oral doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR2285 tablet</intervention_name>
    <description>Pharmaceutical form: SHR2285 tablet Route of administration: single dose and multiple doses.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>SHR2285</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Placebo tablet Route of administration: single dose and multiple doses.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>SHR2285</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. males or females, aged 18-45.&#xD;
&#xD;
          2. subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP&lt;140mmHg;&#xD;
             50mmHg ≤DBP&lt;90mmHg and 50 ≤ HR &lt;110 beats / min.&#xD;
&#xD;
          3. body mass index (BMI) between 18 to 28.&#xD;
&#xD;
          4. Participant in general good health. No clinically significant findings in vital signs,&#xD;
             physical examination, 12-lead ECG ,X-ray and laboratory parameters.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. males or females, aged 18-45.&#xD;
&#xD;
          2. subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP&lt;140mmHg;&#xD;
             50mmHg ≤DBP&lt;90mmHg and 50 ≤ HR &lt;110 beats / min.&#xD;
&#xD;
          3. body mass index (BMI) between 18 to 28.&#xD;
&#xD;
          4. Participant in general good health. No clinically significant findings in vital signs,&#xD;
             physical examination, 12-lead ECG ,X-ray and laboratory parameters.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total&#xD;
             bilirubin/direct bilirubin &gt; 1X ULN during screening/baseline.&#xD;
&#xD;
          2. Serum creatinine&gt; 1X ULN during screening/baseline.&#xD;
&#xD;
          3. Abnormal coagulation function.&#xD;
&#xD;
          4. A clinical history of coagulation dysfunction; subjects with adverse reaction of&#xD;
             antiplatelet drugs or anticoagulant drugs.&#xD;
&#xD;
          5. Subjects with severe head trauma or head surgery within 2 years or surgery within 3&#xD;
             months prior to the screening.&#xD;
&#xD;
          6. Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before&#xD;
             administration.&#xD;
&#xD;
          7. Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination,&#xD;
             hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were&#xD;
             positive.&#xD;
&#xD;
        8.3 months prior to screening involved in any drug or medical device clinical studies or&#xD;
        within 5 half-life of drugs before screening.&#xD;
&#xD;
        9.Female subjects who did not receive contraception at least 30 days before administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhejing Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

